Walder Wyss’ IP team successfully represented the pharmaceutical company Merck in appeal proceedings before the Swiss Federal Supreme Court against its US competitor MSD. The case Following World War I, Merck’s US subsidiary, which
Nater Dallafior‘s expert on IP/IT and media Mathis Berger (pictured) advised the German Football League (DFL Deutsche Fussball Liga) on all Swiss law aspects of the sale of television rights for the German
Santhera Pharmaceuticals Holding announced the closing of the first tranche of its financing arrangement with a fund managed by Highbridge Capital Management. The team was led by partner Matthias Courvoisier (Capital Markets) and senior associate
The team was led by partner Stefan Knobloch (Corporate/M&A - pictured) and managing associate Fabienne Anner (Corporate/M&A)
The team consisted of partner Matthias Courvoisier, senior associate Yves Mauchle and trainee Jan Lusti
P+P Poellath + Partners and Würtenberger Partnerschaft von Rechtsanwälten acted as legal advisors to Zur Rose. In house strategy was carried out by Chief Strategy and Digital Officer Betul Susamis Unaran.
The team was led by partner Jürg Frick (Banking and Finance - pictured) and included partner Stefan Oesterhelt (Tax) as well as associates Stefan Bindschedler and Alexander Wherlock (both Banking and Finance).
The law firm advised Swiss Re on the update of its USD 10 billion debt issuance programme and the offering of EUR 800 million guaranteed Subordinated Notes, as well as SGD 350 million guaranteed subordinated notes
The team was led by partner Andreas Müller (Corporate/M&A, Technology and Digital Economy - pictured) and included partners Richard Stäuber
The team included partner Matthias Staehelin (pictured), managing associates Moritz Jäggy and Dania Salvisberg-Schneider (all Corporate).